Company intelligence / Profile preview

Hubei Bio-Pharmaceutical Industrial Technological Institute

Wuhan, Hubei Province, 中国（China）en.hbhypharm.com ↗

Ownership: Private
Development stage: Commercial

Overview

Hubei Bio-Pharmaceutical Industrial Technological Institute is developing small molecule drugs targeting oncology and neurological indications. Its lead disclosed asset is a Mat2A inhibitor for neoplasms, currently in preclinical development. The institute has also published on HW161023, an orally active AAK1 inhibitor with potential for neuropathic pain, showing promising preclinical pharmacokinetics and safety profile compared to clinical-stage comparators. No clinical results are available yet.

Therapeutic areas: OncologyNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

5 assets

HW252001

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Hubei Bio-Pharmaceutical Industrial Technological Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hubei Bio-Pharmaceutical Industrial Technological Institute.

Explore the full profile